Virulence Factors Of Carbapenem-Resistant Pseudomonas aeruginosa In Hospital-Acquired Infections In Mansoura, Egypt

Figures & data

Table 1 Specific Primers Used In This Study

Gene	Sequence (5′–3′)	Product Size (bp)	Reference
blaIMP	GGAATAGAGTGGCTTAAYTCTC GGTTTAAYAAAACAACCACC	232	15
blaVIM	GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG	390	15
blaOXA-48	GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG	438	15
blaNDM	GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC	621	15
blaKPC	CGTCTAGTTCTGCTGTCTTG CTTGTCATCCTTGTTAGGCG	798 232	15
lasR	AAGTGGAAAATTGGAGTGGAG GTAGTTGCCGACGACGATGAAG	130	16
rhlR	TGCATTTTATCGATCAGGGC CACTTCCTTTTCCAGGACG	133	16

Table 2 Comparison Of Antibiotic Resistance And Virulence Factors In Carbapenem-Resistant P. aeruginosa And The Carbapenem-Susceptible P. aeruginosa

Variable	Carbapenem-Resistant P. aeruginosa (34)	Carbapenem-Susceptible P. aeruginosa (46)	P value	Odds Ratio		CI
MDR	31(91.2%)	27(58.7)	0.001	7.272		(1.938–27.287)
Ceftazidime	(33) 97.1%	35 (76.1%)	0.009	10.371		(1.268–84.833)
Cefepime	33 (97.1%)	31 (67.4%)	0.001	15.968		(1.989–128.166)
Aztreonam	28 (82.4%)	22 (47.8%)	0.002	5.091		(1.773–14.615)
Piperacillin-tazobactam	21 (61.8%)	17 (37.0%)	0.028	2.756		(1.104–6.879)
Piperacillin	31 (91.2%)	31 (67.4%)	0.012	5		(1.315–19.016)
Gentamicin	29 (85.3)	27(58.7%)	0.010	4.081		(1.337–12.458)
Amikacin	28 (82.4%)	23 (50.0%)	0.003	4.667		(1.626–13.393)
Tobramycin	26(76.5%)	28 (60.9%)	0.141	2.089		(0.777–5.618)
Ciprofloxacin	21 (63.6%)	24 (52.2%)	0.310	1.604		(0.642–4.006)
Levofloxacin	20 (58.8%)	24 (58.8%)	0.555	1.310		(0.535–3.205)
Colistin	0	0	NA	NA		NA
Polymyxin B	0	0	NA	NA		NA
Virulence factors
Protease	25(73.5%)	36(78.3%)	0.623	0.772		(0.274–2.172)
Biofilm	32(94.1%)	30 (65.2%)	0.002	8.533		(1.807–40.288)
Pyocyanin	0.153±0.053	0.179±0.036	0.012			(0.005742–0.045278)
Hemolysin	32(94.1%)	43 (93.5%)	0.907	1.116		(0.176–7.077)
Twitching motility	30 (88.3)	37 (80.4)	0.35	1.824		(0.511–6.512)

Abbreviation: NA, not applicable.

Figure 1 Virulence factors in MDR and non-MDR P. aeruginosa strains.